D7913N00017 - An Open Label, Multi-center, IRESSA Clinical Access Program of Gefitinib 250 mg (IRESSA) for the continued treatment of patients in the United States who are currently benefiting or have benefited from gefitinib treatment
|Effective start/end date||9/1/11 → 12/31/14|
- United BioSource Corporation
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.